Postinfectious irritable bowel syndrome in children
DOI: 10.32364/2618-8430-2021-4-3-292-297
D.V. Pechkurov, A.A. Tyazheva
Samara State Medical University, Samara, Russian Federation
Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders in adults, children, and adolescents. This paper reviews the etiology and pathogenesis of IBS, particularly one of its subtypes, postinfectious IBS, associated with a prior acute intestinal infection. The authors discuss risk factors, diagnosis, and treatment for postinfectious IBS and describe diagnostic search and therapeutic algorithm in a child. Treatment for IBS involves changes in diet and lifestyle, pharmacotherapy, and psychotherapy.This case report is interesting for clinicians since only attempts are made to systematize guidelines on the diagnosis and treatment for postinfectious IBS. However, specific management strategies for this condition are scarce, making the diagnosis difficult and resulting in treatment delay.
Keywords: irritable bowel syndrome, functional gastrointestinal disorders, prokinetic agent, synbiotic, Maxilac.
For citation: Pechkurov D.V., Tyazheva A.A. Postinfectious irritable bowel syndrome in children. Russian Journal of Woman and Child Health. 2021;4(3):292–297 (in Russ.). DOI: 10.32364/2618-8430-2021-4-3-292-297.
References
1. Ivashkin V.T., Shelygin Yu.A., Baranskaya E.K. and other Clinical guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia for the diagnosis and treatment of irritable bowel syndrome. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2017;27(5):76–93 (in Russ.). DOI: 10.22416/1382-4376-2017-27-5-76-93.
2. Lovell R.M., Ford A.C. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721. DOI: 10.1016/j.cgh.2012.02.029.
3. Kornienko E.A. Inflammatory bowel disease in children. M.: Prima Print; 2014 (in Russ.).
4. Rasquin A., Di Lorenzo C., Forbes D. et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006;130(5):1527–1537. DOI: 10.1053/j.gastro.2005.08.063.
5. Pechkurov D.V., Allenova Yu.E., Tyazheva A.A. Age features of functional disorders of the gastrointestinal tract, manifested by abdominal pain, from the standpoint of the biopsychosocial model. Voprosy detskoy diyetologii. 2015;13(2):11–15 (in Russ.).
6. Naletov A.V., Vyunichenko Yu.S., Koktyshev I.V. Influence of parental compliance on quality of life indicators in the treatment of children with irritable bowel syndrome. Dal’nevostochnyy meditsinskiy zhurnal. 2018;4:28–32 (in Russ.).
7. Mnatsakanyan M.G., Pogromov A.P., Dyukova G.M., Tashchyan O.V. Emotional and personal characteristics and quality of life in women with irritable bowel syndrome. Meditsinskiy alfavit. 2017;2(19):22–27 (in Russ.).
8. Maev I.V., Samsonov A.A., Yashina A.V. et al. New possibilities in the treatment of irritable bowel syndrome: an effective approach and correction of the quality of life. Farmateca. 2016;15(328):12–18 (in Russ.).
9. Belmer S.V., Volynets G.V., Gorelov A.V. et al. Functional disorders of the digestive system in children. Recommendations of the Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists. Part 2. Russian Bulletin of Perinatology and Pediatrics. 2020;65(5):100–111 (in Russ.). DOI: 10.21508/1027-4065-2020-65-5-100-111.
10. Drossman D.A., Hasler W.L. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–1261. DOI: 10.1053/j.gastro.2016.03.035.
11. Qin H.Y., Cheng C.W., Tang X.D., Bian Z.X. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014;20(39):14126–1431. DOI: 10.3748/wjg.v20.i39.14126.
12. Kovaleva A.L., Poluektova E.A., Shifrin O.S. Intestinal barrier, intestinal permeability, nonspecific inflammation and their role in the formation of functional diseases of the gastrointestinal tract. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2020;30(4):52–59 (in Russ.). DOI: 10.22416/1382-4376-2020-30-4-52-59.
13. Gaus O.V., Livzan M.A. Fundamentals of the formation of abdominal pain in patients with irritable bowel syndrome. Effektivnaya farmakoterapiya. 2020;16(15):102–111 (in Russ.). DOI: 10.33978/2307-3586-2020-16-15-102-111.
14. Spence M.J., Moss-Morris R. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut. 2007;56:1066–1071.
15. Schwille-Kiuntke J., Mazurak N., Enck P. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers’ diarrhoea. Aliment Pharmacol Ther. 2015;41:1029–1037. DOI: 10.1111/apt.13199.
16. Stewart G.T. Post-dysenteric colitis. Br Med J. 1950;1(4650):405–409. DOI: 10.1136/bmj.1.4650.405.
17. Samsonov A.A., Plotnikova E.Yu., Borshch M.V. Post-infectious irritable bowel syndrome is a special form of functional intestinal pathology. Lechashchiy vrach. 2012;7:16–21 (in Russ.).
18. Recommendations for pediatrics. A specialized publication for medical and pharmaceutical professionals. Edited by prof. Zakharova I.N. M.: REMEDIUM GROUP; 2019 (in Russ.).
19. Belova A.A., Shestakova M.D., Khavkin A.I. Giardiasis and post-infectious IBS. Eksperimental’naya i klinicheskaya gastroenterologiya. 2021;188(4):178–187 (in Russ.). DOI: 10.31146/1682-8658-ecg-188-4-178-187.
20. Neal K.R., Hebden J., Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314(7083):779–782. DOI: 10.1136/bmj.314.7083.779.
21. Borgaonkar M.R., Ford D.C., Marshall J.K. et al. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci. 2006;51(5):1026–1032. DOI: 10.1007/s10620-006-9348-1.
22. Marshall J.K., Thabane M., Garg A.X. et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131(2):445–450. DOI: 10.1053/j.gastro.2006.05.053.
23. Thabane M., Kottachchi D.T., Marshall J.K. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(4):535–544. DOI: 10.1111/j.1365-2036.2007.03399.x.
24. Gwee K.A. Post-Infectious Irritable Bowel Syndrome, an Inflammation-Immunological Model with Relevance for Other IBS and Functional Dyspepsia. J Neurogastroenterol Motil. 2010;16(1):30–34. DOI: 10.5056/jnm.2010.16.1.30.
25. Balemans D., Mondelaers S.U., Cibert-Goton V. et al. Evidence for long-term sensitization of the bowel in patients with post-infectious-IBS. Sci Rep. 2017;7:13606. Published online 2017 Oct 19. DOI: 10.1038/s41598-017-12618-7.
26. Youmans B.P., Ajami N.J., Jiang Z.D. et al. Characterization of the human gut microbiome during travelers’ diarrhea. Gut Microbes 2015;6:110–119. DOI: 10.1080/19490976.2015.1019693.
27. Jalanka-Tuovinen J., Salojarvi J., Salonen A. et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and inpostinfectious irritable bowel syndrome. Gut. 2014;63(11):1737–1745. DOI: 10.1136/gutjnl-2013-305994.
28. Giovanni B., Madhusudan G., Premysl B. et al. Rome foundation working team report on post-infection irritable bowel syndrome. Gastroenterology. 2019;156(1):46–58.e7. DOI: 10.1053/j.gastro.2018.07.011.
29. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines. (Electronic resource.) URL: https://www.ncbi.nlm.nih.gov/books/NBK350043/ (access date: 25.05.2021).
30. Kornienko E.A., Tipikina M.Yu. Results of a study of the effectiveness of probiotics and correction of intestinal motility in IBS in children. Farmateca. 2014;2(275):33–37 (in Russ.).
2. Lovell R.M., Ford A.C. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721. DOI: 10.1016/j.cgh.2012.02.029.
3. Kornienko E.A. Inflammatory bowel disease in children. M.: Prima Print; 2014 (in Russ.).
4. Rasquin A., Di Lorenzo C., Forbes D. et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006;130(5):1527–1537. DOI: 10.1053/j.gastro.2005.08.063.
5. Pechkurov D.V., Allenova Yu.E., Tyazheva A.A. Age features of functional disorders of the gastrointestinal tract, manifested by abdominal pain, from the standpoint of the biopsychosocial model. Voprosy detskoy diyetologii. 2015;13(2):11–15 (in Russ.).
6. Naletov A.V., Vyunichenko Yu.S., Koktyshev I.V. Influence of parental compliance on quality of life indicators in the treatment of children with irritable bowel syndrome. Dal’nevostochnyy meditsinskiy zhurnal. 2018;4:28–32 (in Russ.).
7. Mnatsakanyan M.G., Pogromov A.P., Dyukova G.M., Tashchyan O.V. Emotional and personal characteristics and quality of life in women with irritable bowel syndrome. Meditsinskiy alfavit. 2017;2(19):22–27 (in Russ.).
8. Maev I.V., Samsonov A.A., Yashina A.V. et al. New possibilities in the treatment of irritable bowel syndrome: an effective approach and correction of the quality of life. Farmateca. 2016;15(328):12–18 (in Russ.).
9. Belmer S.V., Volynets G.V., Gorelov A.V. et al. Functional disorders of the digestive system in children. Recommendations of the Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists. Part 2. Russian Bulletin of Perinatology and Pediatrics. 2020;65(5):100–111 (in Russ.). DOI: 10.21508/1027-4065-2020-65-5-100-111.
10. Drossman D.A., Hasler W.L. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–1261. DOI: 10.1053/j.gastro.2016.03.035.
11. Qin H.Y., Cheng C.W., Tang X.D., Bian Z.X. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014;20(39):14126–1431. DOI: 10.3748/wjg.v20.i39.14126.
12. Kovaleva A.L., Poluektova E.A., Shifrin O.S. Intestinal barrier, intestinal permeability, nonspecific inflammation and their role in the formation of functional diseases of the gastrointestinal tract. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2020;30(4):52–59 (in Russ.). DOI: 10.22416/1382-4376-2020-30-4-52-59.
13. Gaus O.V., Livzan M.A. Fundamentals of the formation of abdominal pain in patients with irritable bowel syndrome. Effektivnaya farmakoterapiya. 2020;16(15):102–111 (in Russ.). DOI: 10.33978/2307-3586-2020-16-15-102-111.
14. Spence M.J., Moss-Morris R. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis. Gut. 2007;56:1066–1071.
15. Schwille-Kiuntke J., Mazurak N., Enck P. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers’ diarrhoea. Aliment Pharmacol Ther. 2015;41:1029–1037. DOI: 10.1111/apt.13199.
16. Stewart G.T. Post-dysenteric colitis. Br Med J. 1950;1(4650):405–409. DOI: 10.1136/bmj.1.4650.405.
17. Samsonov A.A., Plotnikova E.Yu., Borshch M.V. Post-infectious irritable bowel syndrome is a special form of functional intestinal pathology. Lechashchiy vrach. 2012;7:16–21 (in Russ.).
18. Recommendations for pediatrics. A specialized publication for medical and pharmaceutical professionals. Edited by prof. Zakharova I.N. M.: REMEDIUM GROUP; 2019 (in Russ.).
19. Belova A.A., Shestakova M.D., Khavkin A.I. Giardiasis and post-infectious IBS. Eksperimental’naya i klinicheskaya gastroenterologiya. 2021;188(4):178–187 (in Russ.). DOI: 10.31146/1682-8658-ecg-188-4-178-187.
20. Neal K.R., Hebden J., Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ. 1997;314(7083):779–782. DOI: 10.1136/bmj.314.7083.779.
21. Borgaonkar M.R., Ford D.C., Marshall J.K. et al. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci. 2006;51(5):1026–1032. DOI: 10.1007/s10620-006-9348-1.
22. Marshall J.K., Thabane M., Garg A.X. et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131(2):445–450. DOI: 10.1053/j.gastro.2006.05.053.
23. Thabane M., Kottachchi D.T., Marshall J.K. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(4):535–544. DOI: 10.1111/j.1365-2036.2007.03399.x.
24. Gwee K.A. Post-Infectious Irritable Bowel Syndrome, an Inflammation-Immunological Model with Relevance for Other IBS and Functional Dyspepsia. J Neurogastroenterol Motil. 2010;16(1):30–34. DOI: 10.5056/jnm.2010.16.1.30.
25. Balemans D., Mondelaers S.U., Cibert-Goton V. et al. Evidence for long-term sensitization of the bowel in patients with post-infectious-IBS. Sci Rep. 2017;7:13606. Published online 2017 Oct 19. DOI: 10.1038/s41598-017-12618-7.
26. Youmans B.P., Ajami N.J., Jiang Z.D. et al. Characterization of the human gut microbiome during travelers’ diarrhea. Gut Microbes 2015;6:110–119. DOI: 10.1080/19490976.2015.1019693.
27. Jalanka-Tuovinen J., Salojarvi J., Salonen A. et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and inpostinfectious irritable bowel syndrome. Gut. 2014;63(11):1737–1745. DOI: 10.1136/gutjnl-2013-305994.
28. Giovanni B., Madhusudan G., Premysl B. et al. Rome foundation working team report on post-infection irritable bowel syndrome. Gastroenterology. 2019;156(1):46–58.e7. DOI: 10.1053/j.gastro.2018.07.011.
29. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines. (Electronic resource.) URL: https://www.ncbi.nlm.nih.gov/books/NBK350043/ (access date: 25.05.2021).
30. Kornienko E.A., Tipikina M.Yu. Results of a study of the effectiveness of probiotics and correction of intestinal motility in IBS in children. Farmateca. 2014;2(275):33–37 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
